VANCOUVER, Jan. 16, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced that members of its senior scientific and clinical team will be attending the EB2020 World Congress, organized and funded by the Dystrophic Epidermolysis Bullosa Research Association (DEBRA), from January 19-23, 2020 in London, UK.
InMed will be exhibiting preclinical data supporting the potential of its lead product candidate, INM-755, to provide symptomatic relief of EB and potentially increase skin integrity in a subset of patients. The InMed team will also be sharing details of its recently initiated Phase 1 clinical trial with INM-755 in healthy subjects and the near-term clinical program leading to the first study in EB patients. “We are excited to be participating in this EB2020 World Congress, where we will be expanding our engagement with scientific and medical thought leaders, patient advocacy groups, and members of the EB community, all of whom are instrumental in collaborative efforts to address this devastating disease,” said Alexandra Mancini, Senior Vice President, Clinical & Regulatory Affairs at InMed.
Additional information about DEBRA International and the 1st Global International Congress can be found at https://ebworldcongress.org/.
InMed Pharmaceuticals is a clinical stage biopharmaceutical company developing a proprietary biosynthesis platform for the manufacturing of pharmaceutical-grade cannabinoids, as well as a pipeline of cannabinoid-based medications that target diseases with high unmet medical needs.Â The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.Â For more information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws.Â Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.Â Forward-looking information in this news release includes statements about: presenting preclinical data at the EB2020 World Congress, clinically testing and further developing a therapeutic product (INM-755) with potential to treat patients suffering from epidermolysis bullosa and anticipated interactions with stakeholders in the EB disease area. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.Â Known risk factors include, among others: the exhibition at the DEBRA conference may not proceed as planned, or at all; clinical trials may not proceed as anticipated; economic or market conditions may worsen; and InMed’s proprietary biosynthesis manufacturing process and drug development programs may not deliver the expected level of results.Â A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s most recent Annual Information Form and other continuous disclosure filed with Canadian securities regulatory authorities on SEDAR at www.sedar.com.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc.